Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Latest Furor Over Trump’s Drug Pricing Plan

Executive Summary

Did the head of the Office and Management & Budget really endorse Part D rebates? Like so much about the Trump Administration’s response to drug pricing, there is probably a lot less to the story than it sounds.

You may also be interested in...



The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

The US Drug Pricing Hearing Pharma Wants

Senate hearing will examine drug delivery system, but industry still faces possibility of another public shaming about increasing drug costs.

HHS Action On Drug Pricing: Here's Who Secretary Price Is Listening To

HHS is expected to move ahead with action to address high drug prices following a series of stakeholder roundtables held over the past month.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS120662

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel